Fasting earlier or later in day ‘effective strategy for long-term weight loss'
Fasting earlier or later in the day for three months could be an effective strategy for long-term weight loss, research suggests.
Experts found that overweight or obese people who restricted eating to an eight hour 'window' per day shed pounds and managed to keep it off.
The new research, which has not yet been published in a peer-reviewed journal, was presented at the European Congress on Obesity in Malaga.
Lead author Dr Alba Camacho-Cardenosa, from the University of Granada in Spain, said: 'Our study found that restricting the eating window to eight hours at any time of the day for three months can result in significant weight loss for at least a year.
'These benefits can be attributed to the 16-hour fasting window rather than the time of eating.'
A previous randomised controlled trial by the same researchers published in the journal Nature Medicine found that restricting eating to eight hours per day decreased body weight and improved cardiometabolic health.
Their latest study looked at the long-term effects over 12 months for 99 people.
Individuals were split into four groups for 12 weeks – eating in a 12-hour or more window; restricting eating to an eight-hour window starting before 10am; restricting eating to an eight-hour window starting after 1pm; and allowing people to select their own eight-hour window.
All groups were given tips on a Mediterranean diet to help them eat healthier.
The researchers measured body weight, waist and hip circumferences at the start of the trial, after the 12-week plan, and 12 months later.
The study found that, while those eating over 12 hours or longer lost an average of 1.4kg, the time-restricted groups lost more, at around 3kg to 4kg.
Time-restricted groups also had greater reductions in waist and hip circumferences of several centimetres, and had maintained greater weight loss after 12 months.
At the one-year mark, those eating for 12 hours or more had an average body weight increase of 0.4kg, compared with around a 2kg weight loss in the early and late time restricted groups, the study concluded.
Those who chose their own pattern also maintained some weight loss although this was not statistically significant.
Around 85% to 88% of people restricting their eating window also found they stuck to the plan.
Dr Jonatan Ruiz, study co-ordinator from the University of Granada, said: 'This kind of intermittent fasting appears feasible for adults with overweight or obesity who wish to have a relatively simple way of losing and maintaining weight loss that is less tedious and more time efficient compared with daily calorie counting, but it warrants further investigations in larger and longer-term studies.'
Dr Maria Chondronikola, principal investigator and lead for human nutrition at University of Cambridge Metabolic Research Laboratories, said further studies were needed.
'Understanding how well participants adhered to the timing of their meals, the level of their caloric intake and whether time-restricted eating changed any obesity-related metabolic outcomes would provide valuable insight into the true effectiveness of time-restricted eating,' she said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
40 minutes ago
- The Independent
Weight-loss drugs were said to be a game changer. Turns out the benefit might be thinner than thought
Common GLP-1 weight loss drugs - including Wegovy and Ozempic - may not work for everyone in a 'real-world' setting, Cleveland Clinic researchers said Tuesday. The reason is that patients may take lower dosages or discontinue their treatment, negatively impacting the ability to control blood sugar levels in those who are pre-diabetic. The findings may have implications for people considering using the drugs, that are taken by more than eight million Americans every year. They've offered an alternative to traditional and taxing weight loss methods, such as diets and fitness. 'Our study shows that patients treated for obesity with semaglutide or trizepatide lost less weight on average in a regular clinical setting compared to what is observed in randomized clinical trials,' Dr. Hamlet Gasoyan, a researcher with Cleveland Clinic, said in a statement. 'According to our data, this could be explained by higher rates of discontinuation and lower maintenance dosages used in clinical practice, compared to randomized clinical trial settings.' Gasoyan was the lead author of the study published on Tuesday in the Obesity Journal. A request for comment from the drugmakers Novo Nordisk and Eli Lilly was not immediately returned to The Independent. The study focuses on drugs with the active ingredients semaglutide and tirzepatide; they include the U.S. Food and Drug-administration approved type 2 diabetes medications Zepbound and Mounjaro. The authors studied their effects on weight loss and blood sugar regulation in a real-world setting. They noted that previous randomized clinical trials have shown the efficacy of those medications. The authors monitored the health of nearly 7,900 adults who were severely obese. Of those, more than 1,300 had pre-diabetes at the study's start and were at a higher risk for developing type 2 diabetes: a chronic condition that affects a person's ability to use insulin and keep blood sugar at normal levels. Participants took the shots between 2021 and 2023. The researchers sorted patients who discontinued their obesity medications into two groups: those who did it within just three months and by three months to a year. The study's follow-up period ended last December. The most common reasoning for discontinuation of treatment in the real-world setting was due to the steep cost of the drugs and insurance, side effects and shortages. Notably, since the study's, prices have started to fall. Of the participants, more than 20 percent discontinued their medications early and 32 percent discontinued their medications late. Furthermore, the authors noted than more than 80 percent had been on the lower dosages needed to sustain a therapeutic effect. For semaglutide, that's equal to or less than 1 milligram and equal to or less than 7.5 milligrams for tirzepatide. Following a year of treatment, the average weight reduction was 3.6 percent among participants who discontinued their treatment early, compared to 6.8 percent for those who discontinued their treatment late. But, those who did not discontinue treatment and were on the highest dosages necessary lost the most weight, at up to 13.7 percent with semaglutide and 18 percent with tirzepatide. Participants had higher odds of achieving 10 percent or greater weight reduction after one year of treatment if they did not discontinue their medications or did so late, were on the highest dosages needed for a therapeutic effect, received tirzepatide, and were women. Tracking the maintenance of blood sugar levels in those with pre-diabetes, the researchers said just a third of those who discontinued their treatment early experienced normal blood sugar levels compared to 41 percent who discontinued their treatment late and 67.9 percent who did not discontinue treatment. Lastly, the researchers observed that while patients who discontinued obesity medications lost significantly less weight compared to those who did not, their weight trajectories remained relatively stable. They said that would be the subject of additional research. 'Our findings about the real-world use patterns of these medications and associated clinical outcomes could inform the decisions of healthcare providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight reductions,' explained Gasoyan.
Daily Mail
2 hours ago
- Daily Mail
Women who have weekly sex are happier in relationships, study finds
A new study has revealed that women who have sex at least once a week are the 'happiest' in their relationship. Scientists found 85 per cent of women who had sex once a week described themselves as 'sexually satisfied'. In contrast, only 66 per cent of women who had sex once a month reported the same level of relationship bliss, and the figure fell to 17 per cent among those who had intercourse less than this. Alexandra Janssen, author of the study and researcher at the University of Manchester, told 'While the study shows an association between frequency of sex and sexual relationship satisfaction, this is only a correlation.' Janssen added: We don't know whether women are happier because they are having more sex, if they are having more sex because they are happier, or if they are happier and having more sex because of other factors-perhaps they don't have kids. Also, the fact that women who have less sex are also less satisfied in their relationship isn't particularly surprising.' The data showed that satisfaction was also higher for women who reported more regular orgasms and rated sex as an important part of their life. Janssen went on: 'What I found interesting in the study was that, while women who orgasmed more frequently were generally happier in their sex lives, women who orgasmed 100 per cent of the time weren't the most satisfied. 'This contradicts the belief that women are most satisfied when they have an orgasm at every sexual encounter. It shows that women don't have to orgasm every time they have sex to be satisfied in their relationship. I hope that this takes the pressure off women who might struggle to achieve orgasm 100 per cent of the time.' Janssen's study also found that women who rated sex as 'very important' had happier love lives than those who did not. Other findings from the study, published in the International Journal Of Sexual Health, found that of the women surveyed those aged 18 to 24 were most likely to report being sexually satisfied. In contrast, women over the age of 45 were the least likely to report being happy with their intimate relationship. The study was based on a survey of 483 women from New Zealand who had been in a committed relationship within the past year. The authors noted their study did have some limitations. One was that being a survey, there was no way to verify if what the women reported was true. Another was that the group of predominantly heterosexual women surveyed was not very diverse, which could limit the scope of findings to other groups.
Telegraph
2 hours ago
- Telegraph
NHS to offer women under 50 fewer cervical screenings
Millions of women will be offered NHS cervical screening less often under radical plans. Those below the age of 50 will be called forward every five years instead of three. The changes were announced on Tuesday by NHS England, who said they were backed by clinical evidence that just as many cancer cases would be detected. Health chiefs said the changes would enable 'millions of women and people with a cervix in England to benefit from more personalised cervical screening' from next month. Under the NHS screening system, which replaced smears, cells are tested for the presence of Human Papillomavirus (HPV), which causes almost all cervical cancer. Currently, women aged 25 to 49 in England are offered such checks every three years, with screening every five years for those aged 50 to 64. If HPV is detected, checks are repeatedly annually, with further investigations if any cell abnormalities are found. More regular screening is also offered to those with a recent history of HPV. Under the new system, checks on those with positive results will remain as regular. But the standard gap for those who test negative will extend from three years to five for women aged 25 to 49. This puts it in line with the gap for older women, in a similar approach to that adopted by Australia, the Netherlands and Sweden. Under the NHS plan, if a woman aged between 25 and 49 had a negative result, but previously had a positive test, they would still get a test three years later. Health chiefs said the new approach was more 'personalised' than previous approaches. Screening will also continue to be offered to trans men if they still have a cervix. The NHS has this week rolled-out digital invitations and reminders for cervical screening via the NHS App, as part of a new 'ping and book' service to boost uptake and help save thousands of lives. Eligible women will first receive a notification through the app to alert them to book a screening appointment, followed by a text message if the app notification is not opened. Letters will remain in place for those who need them. DIY tests It comes as the health service prepares to roll out DIY tests allowing women to 'self-sample' at home if the prefer. Health officials have said such tests could be rolled out as soon as January if the move is recommended by the UK National Screening Committee. The self-checks will allow those who do not attend appointments the option to do their own tests at home, ordering the kit on the app. The NHS said the rollout of testing, which is far more accurate than older methods, means women will be able to safely have longer gaps between screening. Studies have shown that if a patient tests negative for HPV they are extremely unlikely to go on to develop cervical cancer within the next decade. Research on a pilot scheme involving 1.3 million women, led by King's College London researchers and published in the BMJ in 2022, showed that five-yearly screening is as safe as three-yearly, that the same number of cancers are found and less frequent cervical screening tests are needed. It comes after they considered evidence, including a 2022 study of 1.3 million women in England. Some other countries, including Wales and Scotland, have already extended the gap to five years, after it was recommended by the UK National Screening Committee in 2019. Other countries have gone further. In Sweden, women aged 23 to 49 have checks every five years with seven year intervals for those aged 50 to 70. In the Netherlands, women are invited for screening every five years from the age of 30. If a woman tests HPV negative after the age of 40 the screening interval is extended to 10 years. Australia – which aims to become the first country in the world to eliminate cervical cancer – offers checks every 5 years for women aged 25 to 74. The NHS in England has urged women to come forward for cervical screening, with latest figures showing more than 5 million are not up to date with check-ups. Dr Sue Mann, the NHS's national clinical director for women's health, said: 'Taking a more personalised approach to cervical screening will help ensure everyone eligible can make the most of these life-saving services, while sparing them appointments that they don't need. 'The NHS is following robust evidence on how often women need to be safely screened, and by putting invitations and reminders straight in women's pockets on their phones, we're making it easier than ever to take up screening appointments. 'Make sure you come forward for your screening when you're invited, even if it was weeks, months or years ago. If you think you are due but have not yet had an invitation, speak to your GP practice.' For decades, the NHS offered smear tests, which checked cervical cells for abnormalities. If abnormalities were found samples were tested for HPV. But since 2019, the system has been changed so the tests check for HPV in the first instance. Cell abnormalities As HPV infection comes before cell abnormalities develop, the new system has been found to be more accurate and to detect more women who may be at risk. NHS officials have pledged to eliminate cervical cancer by 2040. Michelle Mitchell, the chief executive of Cancer Research UK, said: 'We welcome this change to cervical screening in England, which is the result of years of vital research to make screening more effective and has shown it is safe to extend the time between tests. 'Screening, alongside the roll out of the HPV vaccine – which Cancer Research UK scientists helped develop – have seen cervical cancer rates drop by around a quarter since the early 1990s, and we look forward to even more progress.' Athena Lamnisos, the chief executive of The Eve Appeal, a cancer charity, said: 'Every single case of cancer that can be prevented, should be, and this new guidance is good news for those at low risk because they will no longer need to go for cervical screening as often.'
